Cargando…
Novel Molecular Markers in Glioblastoma—Benefits of Liquid Biopsy
Glioblastoma is a primary Central Nervous System (CNS) malignancy with poor survival. Treatment options are scarce and despite the extremely heterogeneous nature of the disease, clinicians lack prognostic and predictive markers to characterize patients with different outcomes. Certain immunohistoche...
Autores principales: | Birkó, Zsuzsanna, Nagy, Bálint, Klekner, Álmos, Virga, József |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589793/ https://www.ncbi.nlm.nih.gov/pubmed/33053907 http://dx.doi.org/10.3390/ijms21207522 |
Ejemplares similares
-
Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity
por: Hutóczki, Gábor, et al.
Publicado: (2021) -
Analysis of Circulating miRNA Profile in Plasma Samples of Glioblastoma Patients
por: Géczi, Dóra, et al.
Publicado: (2021) -
Extracellular matrix differences in glioblastoma patients with different prognoses
por: Virga, József, et al.
Publicado: (2019) -
Liquid Biopsy in Glioblastoma
por: Ronvaux, Lorian, et al.
Publicado: (2022) -
Liquid biopsy and glioblastoma
por: Eibl, Robert H., et al.
Publicado: (2023)